Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019-Reference-Cited by-同舟云学术

Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019

Published:2022-09-01 Issue:3 Volume:76 Page:e503-e506
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Awasthi Mayanka¹,Golding Hana¹,Khurana Surender¹

Affiliation:

1. Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA

Abstract

Abstract Our study demonstrates that neither 2020 convalescent plasma (CP) nor 2019/2020 intravenous immunoglobulin (IVIG) neutralizes Omicron subvariants BA.1 to BA.5. In contrast, 2020 hyperimmune anti–severe acute respiratory syndrome coronavirus 2 IVIG (hCoV-2IG) lots neutralized Omicron variants of concern, similar to results with 2022 CP from BA.1 breakthrough infections. Therefore, high-titer hCoV-2IG and CP could be evaluated for treatment of high-risk individuals infected with circulating Omicron subvariants.

Funder

Department of Health and Human Services

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac642/45634275/ciac642.pdf

Reference14 articles.

1. Convalescent plasma antibody levels and the risk of death from COVID-19;Joyner;N Engl J Med,2021

2. Transfusing convalescent plasma as post-exposure prophylaxis against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a double-blinded, phase 2 randomized, controlled trial;Shoham;Clin Infect Dis,2023

3. Clinical applications of intravenous immunoglobulins (IVIg)—beyond immunodeficiencies and neurology;Hartung;Clin Exp Immunol,2009